Rishi R Lulla, Allen Buxton, Mark D Krailo, Margot A Lazow, Daniel R Boue, James L Leach, Tong Lin, James I Geller, Shiva Senthil Kumar, Marina N Nikiforova, Uma Chandran, Sachin S Jogal, Marvin D Nelson, Arzu Onar-Thomas, Daphne A Haas-Kogan, Kenneth J Cohen, Mark W Kieran, Amar Gajjar, Rachid Drissi, Ian F Pollack, Maryam Fouladi
BACKGROUND: Outcomes for children with high-grade gliomas (HGG) remain poor. This multicenter phase II trial evaluated whether concurrent use of vorinostat or bevacizumab with focal radiotherapy (RT) improved 1-year event-free survival (EFS) compared to temozolomide in children with newly diagnosed HGG who received maintenance temozolomide and bevacizumab. METHODS: Patients ≥ 3 and < 22 years with localized, non-brainstem HGG were randomized to receive RT (dose 54-59...
2024: Neuro-oncology advances